CompletedPhase 4

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

United States20 participantsStarted 2013-07

Plain-language summary

Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * NAION 6 months prior to enrollment * visual acuity of 20/40 or worse Exclusion Criteria: Current use of Dalfampridine (Ampyra) * Pregnancy * History of seizures * Renal Failure * Not able to perform testing

What they're measuring

Improve visual function

Timeframe: two weeks

Trial details

NCT IDNCT01975324

SponsorNeuro-Ophthalmologic Associates, PC

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-12

View on ClinicalTrials.gov More Non Arteritic Ischemic Optic Neuropathy trials